Nabsys
- Company typePrivate
- Founded2005
- HeadquartersProvidence, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
Nabsys firmographics
Firmographics- Name
- Nabsys
- Legal name
- Nabsys 2.0 LLC
- Website
- https://nabsys.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Nabsys industry classification
Industry- Product category
- Genomics Instrumentation
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
- SIC
- Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)
- akta.pro secondary industry
- Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK)
Keywords
Where Nabsys is headquartered
LocationHeadquarters
- HQ city
- Providence
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Nabsys business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- OhmX Platform Hardware: Sale of the OhmX Analyzer benchtop instrument for genome mapping and structural variant detection.
- Consumables and Reagents: Sale of sample preparation kits including the VOLT Whole Genome Kit and other reagents required for the EGM workflow.
- Software Licenses: Licensing of analytical software including SV-Verify, Human Chromosome Explorer, and RepX Analysis pipelines.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
Nabsys product offering
Product offeringCore offering
Nabsys develops and sells the OhmX Platform, a benchtop Electronic Genome Mapping (EGM) instrument that uses solid-state nanochannel electronic nanodetectors to identify tagged high molecular weight DNA molecules and detect structural variants across the whole genome at 300bp resolution. The product system includes the OhmX Analyzer, nanodetector chips, the VOLT Whole Genome Sample Prep Kit, and secondary analysis software (Human Chromosome Explorer, SV-Verify, and RepX Analysis).
Product overview
Nabsys offers a unified product portfolio centered on its proprietary Electronic Genome Mapping (EGM) technology implemented on the OhmX Platform. The core offering consists of the OhmX Analyzer hardware with integrated nanodetector chips, supported by the OhmX Sample Prep Kit (VOLT) for DNA preparation. Secondary software products include the Human Chromosome Explorer (HCE) for genome assembly and SV analysis, SV-Verify for hypothesis-based structural variant verification using machine learning, and RepX Analysis for repeat expansion disorder detection. The company operates through a partnership with Hitachi High-Tech and offers the OhmX RAMP UP grant program for research laboratories. The technology focuses on structural variant detection in cancer research, rare disease research, repeat expansion disorders, and cell and gene therapy applications.
Differentiator
Problem solved
Functional benefit
Products and services
- OhmX Platform / OhmX Analyzer Benchtop instrument using proprietary electronic nanodetectors to perform whole-genome structural variant detection down to 300bp, with low cost and minimal setup requirements, targeted at translational genomics researchers and clinical cytogenetics labs.
- OhmX VOLT Whole Genome Sample Prep Kit Consumable kit that uses Velocity Optimized Label and Tagging chemistry to tag high molecular weight DNA at sequence-specific sites, enabling same-day amplification-free sample-to-genome-mapping workflow on the OhmX Platform.
- Nanodetector Chips State-of-the-art electronic nano-detector chips installed in the OhmX Analyzer that deliver whole-genome structural variant analysis down to 300bp using HD-Mapping technology.
- Human Chromosome Explorer (HCE) Suite of secondary analytical software tools, co-developed with Hitachi High-Tech, that assembles genomes from OhmX electronic mapping data and identifies structural variants using customer-defined parameters.
- SV-Verify Software Machine-learning software package that performs hypothesis-based verification of putative structural variants using support vector machines, testing several thousand independent deletion hypotheses from 300bp to hundreds of kilobases.
- RepX Analysis Bioinformatics pipeline that analyzes up to 30 repeat-expansion genes in a single workflow, eliminating the need for multiple locus-specific assays in studies of Fragile X, Friedreich's ataxia, FSHD, and similar disorders.
Quantifiable outcome
- Throughput increased by over 10x following technical milestone achievement
- +3 more outcomes
Companies that use Nabsys
Customer profileNamed customers5 records
Segments5 records
Ideal customer profiles3 records
Nabsys technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
Nabsys partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core.
- Leiden University Medical Center (LUMC)coreCollaboration to develop an electronic genome mapping-based assay using the OhmX Platform for facioscapulohumeral muscular dystrophy (FSHD) research, a repeat contraction disease. The partnership aims to address limitations of current diagnostic methods like Southern blot which require radioactivity and significant technical expertise.
- Hitachi High-Tech America (RAMP UP Program)coreRAMP UP (Rapid Application to Market Penetration User Partnership) program collaboration for advancing the OhmX Electronic Genome Mapping Platform. The program includes installations at leading cytogenetic laboratories and sponsored research agreements.
- Columbia University (Dr. Brynn Levy)coreRenowned cytogeneticist joined the RAMP UP program to advance electronic genome mapping applications in hematologic malignancies, beginning with acute myeloid leukemia and myelodysplastic syndromes. Multiple OhmX Platforms installed under sponsored research agreement.
- Brown University (Dr. Martin Taylor Lab)coreResearch collaboration to present data at AGBT 2026 on direct genome-scale mapping of endonuclease activity of human LINE-1 ORF2p using EGM on the OhmX Platform. Dr. Taylor's team demonstrated the technology's capability for genome-wide analysis of DNA modifications and damage.
- Boston Children's HospitalcoreMulti-disciplinary research collaboration using the OhmX Platform for multi-omics studies. Researchers presented data on interstitial cystitis/bladder pain syndrome at ASHG 2025, identifying previously undetected structural variants. Boston Children's Hospital utilized EGM to identify a novel translocation involving NOTCH1.
- Hitachi High-Tech CorporationcoreJoint presentation and demonstration of EGM technology at Japanese Society of Human Genetics 2025 Annual Meeting. Partnership on development and release of Human Chromosome Explorer secondary analytical software tools.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
Nabsys competitors and assessment
Company assessmentOthers
- QIAGEN: Sample-prep and molecular diagnostics consumables supplier. Comparable as a supplier of nucleic acid preparation and analysis tools used in genomics workflows that include Nabsys-adjacent applications.
Broad incumbents
- Agilent Technologies: Analytical instrument and molecular diagnostics company serving genomics and pathology labs. Competes for benchtop instrument budgets in cytogenetics and molecular pathology workflows.
- Illumina: Dominant short-read sequencing incumbent whose installed base generates the SV-calls that Nabsys's orthogonal validation product (SV-Verify) is designed to verify. Competes indirectly as the default workflow in many genomics labs.
- Thermo Fisher Scientific: Life sciences tools giant with broad genomics, cell therapy, and analytical instrument portfolios. Competes indirectly across multiple Nabsys application areas through instruments and consumables.
- 10x Genomics: Genomics tools company offering linked-read sequencing, single-cell, and spatial platforms. Competes for genomics-research capital budgets and offers complementary workflows in cancer and rare disease.
Direct peers
- Pacific Biosciences: Long-read sequencing platform (HiFi) increasingly used for structural variant detection and de novo assembly. Competes with Nabsys for SV-detection budgets in genomics labs, though with a different detection modality.
- Bionano Genomics: Direct competitor offering optical genome mapping for structural variant detection. Most analogous peer as both companies sell benchtop mapping instruments with consumables for SV analysis in cytogenetics and rare disease workflows.
- Oxford Nanopore Technologies: Long-read sequencing platform used for SV detection, repeat expansion analysis, and rare disease research. Directly competes with OhmX in repeat expansion and structural variant applications.
Emerging players
- Singular Genomics: Benchtop sequencing platform targeting multiomic applications including cytogenetics. Overlaps with Nabsys in serving genomics labs with benchtop instruments, though using a different detection chemistry.
- Element Biosciences: Sequencing platform company offering benchtop sequencers targeting lower-cost, higher-throughput genomics. Competes for genomics lab budgets though not directly in SV detection today.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Nabsys social profiles
Digital presenceNabsys compliance and trust
Trust signalCompliance1 record
Nabsys financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nabsys leadership team
Management profileNumber of profiles
Profiles8 records
Nabsys funding detail
Funding detailFunding overview
Funding rounds9 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nabsys M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nabsys
What does Nabsys do?
Nabsys develops and sells the OhmX Platform, a benchtop Electronic Genome Mapping (EGM) instrument that uses solid-state nanochannel electronic nanodetectors to identify tagged high molecular weight DNA molecules and detect structural variants across the whole genome at 300bp resolution. The product system includes the OhmX Analyzer, nanodetector chips, the VOLT Whole Genome Sample Prep Kit, and secondary analysis software (Human Chromosome Explorer, SV-Verify, and RepX Analysis).
Is Nabsys a public or private company?
Nabsys is a private company. It is classified as corporate owned and is currently operating.
When was Nabsys founded?
Nabsys was founded in 2005. It employs 51 to 100 people.
Where is Nabsys based?
Nabsys is headquartered in Providence, United States, in the North America region.
How does Nabsys make money?
Three revenue lines are on record. OhmX Platform Hardware is the primary driver. The others are consumables and Reagents and software Licenses.
Who are Nabsys's main competitors?
QIAGEN is listed as an others. Broad incumbents are Agilent Technologies, Illumina, Thermo Fisher Scientific and 10x Genomics. Direct peers are Pacific Biosciences, Bionano Genomics and Oxford Nanopore Technologies. Emerging players are Singular Genomics and Element Biosciences.
Does Nabsys have an API?
No public API is recorded for Nabsys.
What industry is Nabsys in?
Nabsys's product category is Genomics Instrumentation. Its primary akta.pro industry code is HLAFAMAE, Molecular Diagnostics & Genomics Laboratories, with a secondary code of HDAHALAK, Biosensors & Lab-on-Chip (BioMEMS). Its NAICS code is 541714 and its SIC code is 3826.